Oral single-ingredient berberine hydrochloride,
does it really help with Reduction of HbA1c in adults with type 2 diabetes?
research showsGrade C with 54 points. In the PREMOTE study, least-squares mean HbA1c change at week 13 was -0.99 percentage points in the berberine-only active-ingredient arm and -0.59 with double placebo, a between-group difference of -0.40 (95% CI -0.67 to -0.13; adjusted P=.0006). All groups first received seven days of gentamicin and the product was supplied by a manufacturer, limiting transfer to ordinary supplements.
ads claimDo not claim the same effect without the antibiotic pretreatment, replacement of metformin, cure or complication prevention, or interchangeability of all berberine products.
Useful facts when choosing a product
- This verdict applies only to the displayed formulation, route, dose, duration, population, endpoint, and comparator.
- Berberine hydrochloride, botanical extracts, combination formulas, dihydroberberine, other derivatives, and topical products are not interchangeable.
- Warning. Gastrointestinal adverse effects were common and glucose-lowering drugs may compound hypoglycemia risk. Avoid in pregnancy, lactation, and infants, and review CYP2D6, CYP2C9, and CYP3A4 substrate medicines with a clinician.
Chamgap Semantic Classification Code
Permanent code issued
S.berberine-hydrochloride.oral.hba1c.reduce.placeboSupplements and nutraceuticals > Berberine hydrochloride > Oral > Type 2 diabetes HbA1c > Reduction claim > Same gentamicin pretreatment plus double placebo
Bound to week-13 HbA1c in PREMOTE with industrially synthesized berberine hydrochloride 1.2 g/day and common seven-day gentamicin pretreatment; probiotic combination, other glycemic outcomes, and dihydroberberine are separate. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Berberine hydrochloride |
| Source or part used | Industrially synthesized berberine hydrochloride; not a botanical extract |
| Formulation or processing | Single-ingredient berberine hydrochloride tablets |
| Route | Oral |
| Dose | 600 mg twice daily (1.2 g/day) |
| Duration | Seven-day gentamicin pretreatment followed by 12 weeks of trial agent; week-13 assessment |
| Population | Adults with type 2 diabetes |
| Effect or condition | Lower HbA1c |
| Primary endpoint | Between-group difference in absolute HbA1c change at week 13 |
| Comparator | Berberine placebo plus probiotic placebo after the same gentamicin pretreatment |
| Duplicate-detection key | Berberine hydrochloride|Single-ingredient berberine hydrochloride tablets|Oral|Adults with type 2 diabetes|Lower HbA1c|Seven-day gentamicin pretreatment followed by 12 weeks of trial agent; week-13 assessment |
What the research actually shows
The PREMOTE paper and NCT02861261 registration were checked against the 2008 pilot; the probiotic-combination arm, dihydroberberine, and combination formulas were excluded.
Why this is classified as C (54)
Axes are S/R1/I1/E+/B0/CX. A prespecified primary HbA1c endpoint, precise favorable contrast, and low missingness are strengths, but the surrogate endpoint, single study lineage, and product support yield C/54.
Counterpoint. A 2008 36-person metformin-controlled pilot mainly documented within-group change and was not counted as independent confirmation of this placebo contract.
Rejudgment record. Independent Codex cross-check — One formulation, route, population, claim, principal endpoint, and comparator
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | E+ | Meets the clinically important threshold |
| Precision | CX | No pooled confidence interval could be confirmed |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study) | Prospectively registered, 4-arm, randomized, double-blind, placebo-controlled trial. | Randomized, analyzed, and completed denominators are kept distinct where reported. | Funding, product support, employee authorship, and conflicts were assessed separately. | The principal endpoint contract is preserved; other outcomes remain separate. | Verified estimates are preserved; missing confidence intervals were not invented. | Evidence weight reflects directness, formulation match, hierarchy, and reporting limitations. |
| Efficacy of berberine in patients with type 2 diabetes mellitus | Randomized pilot trial with metformin as the active comparator. | Randomized, analyzed, and completed denominators are kept distinct where reported. | Funding, product support, employee authorship, and conflicts were assessed separately. | The principal endpoint contract is preserved; other outcomes remain separate. | Verified estimates are preserved; missing confidence intervals were not invented. | Evidence weight reflects directness, formulation match, hierarchy, and reporting limitations. |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-09-08).
Final verification and publication gate: Codex · Evidence date: 2026-09-08 · Corrections: 1
Correction log — 1
Corrections applied to this verdict, in chronological order. Changes are logged, not erased.
- 2026-09-14 · English evidence-table placeholder correction — Replaced 2 generic English evidence-table placeholder fields with specific source-bound translations of the retained Korean record. No new research or medical reassessment was performed; grade, score, citations, and evidence date are unchanged. (grade C unchanged)
Cite this verdict
[Chamgap] Berberine Hydrochloride for Type 2 Diabetes HbA1c—The PREMOTE Trial Found a -0.40-Percentage-Point Difference at Week 13 — Evidence Grade C·54. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/blood-sugar/berberine-hydrochloride-type-2-diabetes-hba1c/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.